More on Sequenom (SQNM): Q1 misses on a per share basis as losses increase, but meets revenue...
More on Sequenom (SQNM): Q1 misses on a per share basis as losses increase, but meets revenue estimates. Total sales jumped 158% over the prior year, led by continued growth in diagnostic sales. Total cost of revenues increased, primarily due to the significant increase in its test volumes and costs to support increased testing capacity. Shares +5% AH.
From other sites
at CNBC.com (Dec 3, 2014)
at CNBC.com (Jan 14, 2014)
at CNBC.com (Mar 15, 2013)
at CNBC.com (Apr 25, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs